Celltrion

• Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-end• Omlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentations• Multiple dose strengths and device options broaden treatment flexibility for healthcare professionals INCHEON, SOUTH KOREA – Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other European countries and plans to complete the rollout across Europe by the end of the year. Celltrion is offering Omlyclo® 300 mg in both pre-filled syringe (PFS) and autoinjector (AI) presentations, allowing patients and healthcare professionals a choice of device depending on the treatment setting and individual patient needs. This comprehensive portfolio provides greater flexibility in dose strengths and device options. Celltrion will continue to provide product information to healthcare professionals and institutions as part of its commercial activities across Europe. “The launch of Omlyclo® 300 mg allows us to offer patients and healthcare professionals more convenient and flexible treatment options,” said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. “Building on the first omalizumab biosimilar1 advantage and broad product portfolio, we will continue to strengthen our competitive position in key tenders and work to sustain Omlyclo®’s strong growth momentum across Europe throughout the second half.” About OMLYCLO® (CT-P39, biosimilar omalizumab1) Omlyclo® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair® (omalizumab). In the EU, Omlyclo® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). About Celltrion, Inc.Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. FORWARD-LOOKING STATEMENTCertain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", “anticipates”, the negative of these words or such other variations thereon or comparable terminology.In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. TrademarkXolair® is a registered trademark of Novartis AG. Reference1 European Medicines Agency. Summary of Product Characteristics (SmPC), Omlyclo. [Last Accessed August 2026] 

- Revenue up 45% and operating profit up 86.3% YoY, with a 32.4% operating margin demonstrating solid growth.- High-margin new products grew 76% YoY, accounting for 65% of total biologics revenue.- COGS ratio improved by 5.4 percentage points YoY, reflecting continued improvement in profitability.- Operating margin above 30% was achieved despite continued investment in R&D for future growth.- The company aims to exceed its annual guidance, supported by major market tenders and continued expansion of newly launched products in the second half. INCHEON, South Korea – Celltrion today announced that it recorded consolidated revenue of KRW 1.3937 trillion and operating profit of KRW 451.8 billion for the second quarter of 2026. The results represent year-over-year (YoY) increases of 45% in revenue and 86.3% in operating profit. Following a record quarterly revenue performance in the first quarter, the company also achieved its highest-ever quarterly revenue in the second quarter. Operating margin improved by 7.2 percentage points from a year earlier to 32.4%, demonstrating both strong top-line growth and enhanced profitability. Compared with the preliminary earnings announced on July 3, revenue increased by KRW 93.7 billion and operating profit rose by KRW 21.8 billion. The latest results reflect more than just revenue growth, highlighting qualitative growth driven by a portfolio shift toward new products and improved manufacturing efficiency. Stable sales of key products, strong global sales growth of newly launched high-margin products, and faster-than-expected cost structure improvements contributed to the performance. The results also demonstrated a virtuous business cycle in which profits from commercialized products provide stable financial support for research and development investments to fuel future growth. ▲ High-Margin New Products Continue Strong Growth Across Major Markets, Accounting for 65% of Biologics RevenueSecond-quarter growth was driven by the rapid expansion of high-margin new products[1], while key products including Remsima, Truxima, and Herzuma maintained solid market positions. Truxima ranked No. 1 in market share in the United States, supported by expanded long-term supply agreements, while Remsima maintained its leading position across key markets. Herzuma achieved a record-high market share of 78% in Japan and exceeded 30% market share in Europe. Revenue from new products increased 76% YoY, expanding their contribution to total biologics revenue to 65%. By product, Remsima SC surpassed a 32% market share across the EU5[2] markets, while Zymfentra, the U.S. brand of Remsima SC, has continued to see steady uptake since launch. Yuflyma maintained its leading position in the European adalimumab market and continued to gain market share in the United States through expanded supply capabilities and distribution networks. Vegzelma maintained its leadership position in Europe and strengthened its U.S. growth foundation through formulary listings by two major pharmacy benefit managers (PBMs). Combined quarterly revenue from five newly launched products — Eydenzelt, Avtozma, Omlyclo, Stoboclo and Osenvelt, and Steqeyma — whose global rollout accelerated last year, exceeded KRW 300 billion, up 49% from the previous quarter. Celltrion plans to increase the share of biologics revenue generated by new products to approximately 70% in the second half of the year by continuing to expand launches into additional markets and broaden approved indications. ▲ COGS Ratio Improves to 38%; Product Mix and Manufacturing Efficiency Accelerate Profit GrowthThe cost of sales ratio improved to 38%, down 5.4 percentage points YoY and 2.1 percentage points from the previous quarter. The improvement was driven by a more favorable product mix resulting from the growing contribution of high-margin new products, as well as enhanced cost competitiveness through the depletion of high-cost inventory, higher production yields, and process optimization. This led to the emergence of operating leverage, with operating profit growth significantly exceeding revenue growth. The company expects profitability improvement to accelerate further in the second half as continued top-line growth generates greater economies of scale, alongside more efficient SG&A spending. The profitability improvement reflects a structural change driven by a shift in revenue mix toward new products and enhanced manufacturing competitiveness, rather than one-off factors. As the contribution of new products continues to increase, the foundation for stable earnings growth is expected to strengthen further. ▲ Operating Margin Exceeds 30% After Recognizing R&D Expenses for Future GrowthCelltrion's second-quarter performance was particularly noteworthy compared with previous quarters, as the company achieved a 32.4% operating margin despite recognizing R&D expenses related to future growth. Celltrion continues to invest in R&D—from the discovery of follow-on biosimilars and novel drug candidates to preclinical and clinical studies, regulatory approval, and commercialization—and recognizes the related costs in current-period earnings. Unlike manufacturing-focused business models, this structure entails maintaining the profitability of current products while simultaneously bearing the investment burden required for future pipeline development. Yet Celltrion delivered an operating margin exceeding 30%, demonstrating that the cash-generating capability and the competitiveness of its business provide strong support for continued R&D investment. Celltrion continues to strengthen a business model in which commercial success supports investment in the development of follow-on biosimilars and novel drug candidates, driving new product launches and revenue growth. This has led to growing recognition that the company's value should be assessed not only on its current profitability, but also on the value of its pipeline and long-term growth prospects supported by sustained R&D investment. ▲ Expanding Biosimilar and Novel Drug Pipeline to Strengthen Future Growth DriversBuilding on the launch of 11 biosimilars globally as of last year, Celltrion is accelerating development of its next-generation pipeline. The company plans to build a portfolio of 18 products by 2030, including biosimilars referencing autoimmune disease treatments such as Ocrevus, Cosentyx, and Taltz, as well as oncology therapies such as Keytruda and Darzalex. Supported by the ongoing trend toward relaxed clinical requirements among regulatory authorities, certain follow-on products are expected to benefit from reduced patient enrollment requirements, shorter development timelines, and lower R&D costs.  In novel drug development, the company continues to expand its novel drug portfolio through both in-house R&D and open innovation initiatives, with programs spanning antibody-drug conjugates (ADCs), multispecific antibodies, and obesity treatments. Leveraging the stable cash flows generated by its biosimilar business, Celltrion aims to accelerate its transformation into a global biopharmaceutical company by delivering tangible R&D outcomes from its novel drug pipeline. ▲ Stronger Second-Half Growth Expected; Company Aims to Exceed Full-Year GuidanceCelltrion expects second-half growth to exceed first-half performance as supplies under major tender contracts increase and newly launched products continue to gain market share across key markets. Driven by new product expansion into additional markets, U.S. PBM formulary coverage, deliveries under European public tenders, and year-end inventory stocking by distributors, the company aims to exceed its full-year targets of KRW 5.3 trillion in revenue and KRW 1.8 trillion in operating profit. A Celltrion official said, “Our second-quarter results demonstrated Celltrion’s cash-generating capability and business competitiveness, as we achieved an operating margin exceeding 30% while continuing to invest in R&D for future growth.” The official added, “We will continue to reinvest the stable cash flows generated by our biosimilar business into follow-on products and novel drug development, with the goal of exceeding our full-year performance targets and enhancing long-term corporate value.”[1] New products: Remsima SC (marketed as Zymfentra in the U.S.), Yuflyma, Vegzelma, Steqeyma, Stoboclo·Osenvelt, Avtozma, Omlyclo, and Eydenzelt[2] EU5: Germany, Spain, the United Kingdom, Italy, France

- Completed formulary listings with ESI’s public and private insurance plans and Optum’s public insurance plan, securing reimbursement coverage across 35% of the total U.S. insurance market- Vegzelma recorded 10.6% market share in the U.S. bevacizumab sector in May, with rapid growth expected through expanded reimbursement access- High-margin follow-up products including Omlyclo are scheduled to launch in the U.S. in H2, building on the performance of Celltrion’s existing portfolio [July 7, 2026, KST] Celltrion today announced that Vegzelma (bevacizumab), its treatment for metastatic colorectal cancer and breast cancer, has successfully secured formulary listings with two major pharmacy benefit managers (PBMs) in the United States, establishing a foundation for reimbursement coverage. As Vegzelma has already achieved a market share of over 10% through ‘open market’-focused sales activities, this latest achievement is expected to further accelerate its market share expansion.Vegzelma has recently been listed as a preferred drug on the government and commercial insurance formularies of Express Scripts (ESI), one of the top three PBMs in the United States, as well as on the government insurance formulary of Optum, another major PBM. Reimbursement coverage for ESI government plans and Optum has already taken effect from July 1, while reimbursement coverage for ESI commercial plans is scheduled to begin in January next year.In the U.S. pharmaceutical market, the top three PBMs hold significant influence, accounting for approximately 80% of the total insurance market. If a drug is not listed on formularies managed by PBMs, patients are required to purchase the product at its full price without reimbursement, making access to high-cost treatments practically difficult. Through these PBM formulary listings, Vegzelma has secured reimbursement coverage across more than 35% of the U.S. insurance market, establishing a stable foundation for prescription growth.According to IQVIA, Vegzelma recorded approximately 10.6% market share in the U.S. bevacizumab sector as of May, surpassing double-digit market share for the first time since launch and continuing its growth momentum. This result was achieved through Celltrion USA’s focused strategy targeting the U.S. bevacizumab open market and is considered particularly meaningful as Vegzelma delivered strong performance despite entering the market as a latecomer in a highly competitive environment.The open market is a channel supported by the U.S. government that directly connects healthcare institutions and pharmaceutical companies, where a company’s sales capabilities and product competitiveness serve as key factors for market penetration. With these formulary listings, Vegzelma is expected to further accelerate its market share growth by adding new reimbursement access from insurers to the existing growth momentum generated in the open market. Celltrion plans to continue pursuing formulary listing negotiations with other major PBMs to further strengthen Vegzelma’s growth trajectory.In addition to Vegzelma, Celltrion’s other key products, including SteQeyma (ustekinumab) and Yuflyma (adalimumab), are also continuing to perform well in the U.S. market. The two products recorded market shares of 13.3% and 8.1%, respectively, in the U.S. in May, demonstrating stable prescription growth. Also, SteQeyma ranked second in prescription volume among ustekinumab biosimilars despite intense competition following the launch of seven biosimilar products, underscoring the direct sales competitiveness of Celltrion USA.Alongside the performance of its existing products, Celltrion’s U.S. revenue growth is expected to continue as high-margin follow-up products are launched. In the second half of the year, the subcutaneous (SC) formulation of Avtozma (tocilizumab), a treatment for autoimmune diseases, and Omlyclo (omalizumab) are scheduled to be newly launched in the U.S., further strengthening the company’s portfolio. Also, Omlyclo is expected to launch in the U.S. as a first-mover omalizumab biosimilar, positioning it to rapidly capture the market based on its competitive advantage.“Vegzelma has secured a reimbursement foundation in the U.S. by being listed as a preferred drug on the formularies of major PBMs with significant market influence, and we expect this to further accelerate prescription growth,” said an official from Celltrion. “We will continue to pursue formulary listing negotiations with other major PBMs to build on Vegzelma’s achievements, while strengthening the sales performance of Celltrion’s broader portfolio and expanding our market influence in the United States.” 

Celltrion Revenue increased 35.2% YoY and operating profit surged 77.3%, marking the highest second-quarter performance in the company's history.High-margin newer portfolio exceeded 60% of total revenue, driving improved product mix and operating margin expansion to approximately 33%.Continued growth across the U.S. and Europe, supported by manufacturing expansion and pipeline advancement, further strengthens long-term growth foundation.Second consecutive quarter of outperforming market expectations, with further growth anticipated during the industry’s peak season in the second half. INCHEON, South Korea – Celltrion today announced that it recorded preliminary consolidated revenue of KRW 1.3 trillion and operating profit of KRW 430 billion for the second quarter of 2026. The results represent the strongest second-quarter performance in the company's history, with revenue increasing 35.2% year over year (YoY) and operating profit rising 77.3% YoY. Operating margin also improved significantly from 25% in the prior-year period to approximately 33%, demonstrating both continued top-line growth and improved profitability. The quarter was particularly meaningful as it reflected not only higher sales but also qualitative grwoth driven by a greater contribution from high-margin products and structurally improved cost base. Following its strong first-quarter performance, Celltrion once again exceeded market expectations in the second quarter, underscoring the growing commercial impact of its business competitiveness. The company also surpassed its previously announced second-quarter operating profit target of KRW 400 billion, which had been presented in its business outlook and management plan disclosed earlier this year, further strengthening confidence in the execution of its annual business plan. Furthermore, considering the seasonal characteristics of the biosimilar industry, in which supply volumes for major national tenders and year-end inventory stocking demand are concentrated in the second half of the year, sales growth is expected to accelerate further during the remainder of the year. As a result, expectations are increasing that the company will exceed its full-year performance targets. Transition toward High-Margin Young Portfolio Accelerates Structural Profitability Improvement The strong performance was driven by the rapid growth of newly launched high-margin products in addition to solid sales of the company’s existing flagship products, accelerating the transformation of its product portfolio toward higher-value offerings. Newer products including Remsima SC(marketed as Zymfentra in the U.S.), Yuflyma, and Steqeyma continued to deliver strong growth across major global markets, with the newer portfolio accounting for more than 60% of total revenue.Zymfentra continued to achieve record-high prescription volumes in the United States, while Steqeyma rapidly expanded its market share and established itself among the leading competitors in the U.S. market. Avtozma and Stoboclo/Osenvelt also successfully gained market traction and are emerging as new growth drivers. In Europe, Omlyclo continued to benefit from its first-mover advantage, while Vegzelma maintained its leading market position despite being a later entrant. Avtozma, Yuflyma, and Stoboclo/Osenvelt have also entered a phase of accelerated sales growth and are expected to become key contributors to second-half performance. Profitability is also improving structurally. As most one-off costs associated with the merger have been resolved, the completion of high-cost inventory clearance, the end of R&D amortization, and improved manufacturing yield(Titer Improvement) collectively enhanced the company's cost competitiveness. Celltrion believes these profitability improvements are structural rather than temporary, supported by a higher-margin product mix and improved manufacturing efficiency, providing a solid foundation for sustainable earnings growth. Strengthening Biosimilars, Novel Drug Pipeline, and Manufacturing Capacity to Support Long-Term Growth Beyond its strong financial performance, Celltrion continues to strengthen its long-term growth platform. CT-P55, a biosimilar referencing Cosentyx for autoimmune diseases, is currently undergoing regulatory review in Korea, North America, and other key markets, while regulatory submissions for Herzuma SC are progressing sequentially across major global markets. Development of follow-on biosimilars referencing Keytruda and Darzalex is also progressing as planned. The company plans to expand its biosimilar portfolio to 18 products by 2030 and 41 products by 2038. Novel drug development is also advancing steadily. CT-P70 and CT-P71 have both received U.S. FDA Fast Track Designation, accelerating their clinical development. Celltrion continues to expand R&D investment with the goal of securing a portfolio of 20 novel drug candidates by next year. To support its expanding product portfolio, Celltrion is simultaneously strengthening its global manufacturing network. In Korea, the company is constructing Plants 4 and 5, adding 180,000 liters of drug substance (DS) manufacturing capacity to its existing 250,000-liter production base. In the United States, Celltrion recently announced a 75,000-liter expansion of its Branchburg manufacturing facility in New Jersey, increasing total U.S. capacity to 141,000 liters. The expansion of its U.S. manufacturing site is expected to structurally mitigate tariff and supply chain risks while establishing a stronger foundation for the company's global contract manufacturing (CMO) business, ultimately supporting the company's long-term growth and enterprise value. A Celltrion official said, "Our second-quarter performance demonstrates that our strategy of expanding the newer product portfolio while improving profitability has begun to deliver meaningful results." The official added, "We continue to strengthen our sustainable growth foundation by simultaneously expanding our product portfolio, enhancing manufacturing capabilities, and accelerating novel drug development. As major tender opportunities and continued momentum from newly launched products are expected to support stronger performance in the second half, we remain confident in delivering results that surpass those of the first half while further strengthening our competitiveness as a global biopharmaceutical leader.".

Designed to address limitations of current GLP-1 therapies by maximizing weight reduction while supporting preservation of muscle mass.Comprehensive toxicology studies, including primate studies, are underway as the program enters the final preclinical stage ahead of global clinical development.Positioned as a next-generation platform candidate with potential applicability across obesity, diabetes, and broader metabolic disease indications.Strategic collaboration with Japan-based Scohia Pharma supports development, with Celltrion expected to lead global development and commercialization.Expands Celltrion’s innovative pipeline beyond biosimilars into obesity, ADCs, and other novel therapeutics, reinforcing mid- to long-term growth drivers. INCHEON, South Korea – Celltrion today announced the initiation of primate toxicology studies for its next-generation obesity drug candidate, CT-G32, representing the final preclinical step prior to global clinical development. The company is advancing the program toward submission of an Investigational New Drug (IND) application in the first half of next year.CT-G32 is a next-generation obesity candidate designed to simultaneously engage four targets, including GLP-1 (glucagon-like peptide-1), and is being advanced by Celltrion as a potential first-in-class therapeutic. The candidate is intended to address key limitations observed in the current GLP-1 treatment landscape, including variability in patient response, muscle loss, and treatment durability, while enhancing overall weight reduction efficacy.As the global obesity therapeutics market is projected to exceed USD 100 billion, competition to secure next-generation multi-agonist mechanisms continues to intensify across the pharmaceutical industry. Celltrion aims to position CT-G32 beyond a conventional weight-loss therapy and develop it as a broader metabolic disease platform capable of regulating fat, muscle, and overall energy metabolism.Under the current toxicology program, Celltrion will assess the safety and toxicity profile of CT-G32 in 252 rats and 48 monkeys. The study is expected to provide critical data to support dose selection and safety evaluation for future clinical trials. In parallel, the company plans to further characterize the candidate’s pharmacokinetic (PK) and pharmacodynamic (PD) profile.In earlier preclinical studies, CT-G32 demonstrated superior weight reduction at equivalent doses relative to a benchmark candidate previously under development, while also showing preservation of lean body mass, including muscle.Based on these preclinical findings, Celltrion intends to submit an IND application in the first half of next year and subsequently advance CT-G32 into global clinical development. The company is also evaluating the potential to expand the candidate beyond obesity into additional metabolic disease indications, including diabetes and metabolic dysfunction-associated steatohepatitis (MASH).To support this program, Celltrion has established a strategic collaboration framework with Japan-based Scohia Pharma and is jointly advancing development activities. Celltrion expects to play a leading role across the full value chain, including preclinical and clinical development as well as global commercialization, in order to strengthen its long-term competitiveness in the global market.In parallel with its quadruple-action injectable program, Celltrion is also developing a multi-action oral obesity candidate. Through differentiated treatment options across stages of care, the company seeks to maximize portfolio synergies and build a broader presence in the obesity therapeutics market. Research is currently underway to improve stability and bioavailability, with IND submission for the oral candidate targeted for the second half of 2028.A Celltrion official said, “CT-G32 is being developed as a next-generation candidate intended to address the limitations of current GLP-1-based therapies while extending Celltrion’s reach beyond obesity into broader metabolic disease areas.” The official added, “Leveraging the global development and manufacturing capabilities established through our biosimilar business, Celltrion will continue to expand its innovative pipeline in areas including obesity and ADCs in support of sustainable mid- to long-term growth.”